Williams S, Cho S, Morrison L, Joshi K, et al. Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in t J Med Econ 2026;29:1198-1212.
PMID: 42012856